Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia.

Trial Profile

Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Alzheimer's disease; Vascular dementia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 29 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Additional lead trial centre identified as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top